Loading...
Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts
Pitari, MR Rossi, M Amodio, N Botta, C Morelli, E Federico, C Annamaria Gullà Caracciolo, D Martino, MTD Arbitrio, M
Pitari, MR
Rossi, M
Amodio, N
Botta, C
Morelli, E
Federico, C
Annamaria GullÃ
Caracciolo, D
Martino, MTD
Arbitrio, M
Citations
Altmetric:
Genre
Journal Article
Date
2015-01-01
Advisor
Committee member
Group
Department
Permanent link to this record
Collections
Research Projects
Organizational Units
Journal Issue
DOI
10.18632/oncotarget.4398
Abstract
miR-21 is an oncogenic microRNA (miRNA) with an emerging role as therapeutic target in human malignancies, including multiple myeloma (MM). Here we investigated whether miR-21 is involved in MM-related bone disease (BD). We found that miR-21 expression is dramatically enhanced, while osteoprotegerin (OPG) is strongly reduced, in bone marrow stromal cells (BMSCs) adherent to MM cells. On this basis, we validated the 3'UTR of OPG mRNA as miR-21 target. Constitutive miR-21 inhibition in lentiviral-transduced BMSCs adherent to MM cells restored OPG expression and secretion. Interestingly, miR-21 inhibition reduced RANKL production by BMSCs. Overexpression of protein inhibitor of activated STAT3 (PIAS3), which is a direct and validated target of miR-2, antagonized STAT3-mediated RANKL gene activation. Finally, we demonstrate that constitutive expression of miR-21 inhibitors in BMSCs restores RANKL/OPG balance and dramatically impairs the resorbing activity of mature osteoclasts. Taken together, our data provide proof-of-concept that miR-21 overexpression within MM-microenviroment plays a crucial role in bone resorption/ apposition balance, supporting the design of innovative miR-21 inhibition-based strategies for MM-related BD.
Description
Citation
Citation to related work
Impact Journals, LLC
Has part
Oncotarget
ADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu